IL-17 mediates resistance to anti-VEGF therapy

Nature Medicine

Volumn 19, Issue 9, 2013, Pages 1092-1094

  Maniati, Eleni ^a   Hagemann, Thorsten ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CD11B ANTIGEN; CHEMOKINE; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 17; MATRIX METALLOPROTEINASE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; BLOOD VESSEL; BONE MARROW CELL; ENDOTHELIUM CELL; FIBROBLAST; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; LEWIS CARCINOMA; NONHUMAN; NOTE; OXYGEN SUPPLY; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; STROMA CELL; TH17 CELL; TUMOR MICROENVIRONMENT; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-17; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TH17 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883826749     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3333     Document Type: Note

References (14)

1. 1.Carmeliet, P. & Jain, R.K. Nature 473, 298-307 (2011).
2. Ferrara, N. & Kerbel, R.S. Nature 438, 967-974 (2005).
3. Kieran, M.W., Kalluri, R. & Cho, Y.J. Cold Spring Harb. Perspect. Med. 2, a006593 (2012).
4. Leek, R.D., Harris, A.L. & Lewis, C.E. J. Leukoc. Biol. 56, 423-435 (1994).
5. Holash, J. et al. Science 284, 1994-1998 (1999).
6. Chung, A.S. et al. Nat. Med. 19, 1114-1123 (2013).
7. McMillin, D.W., Negri, J.M. & Mitsiades, C.S. Nat. Rev. Drug Discov. 12, 217-228 (2013).
8. De Palma, M. & Lewis, C. Cancer Cell 23 Issue 3, 277-286 (2013).
9. Du, R. et al. Cancer Cell 13, 206-220 (2008).
10. Bergers, G. & Song, S. Neuro Oncol. 7, 452-464 (2005).
11. De Palma, M. et al. Cancer Cell 8, 211-226 (2005).
12. Gabrilovich, D.I., Ostrand-Rosenberg, S. & Bronte, V. Nat. Rev. Immunol. 12, 253-268 (2012).
13. Crawford, Y. et al. Cancer Cell 15, 21-34 (2009).
14. 14.Shojaei, F. et al. Nat. Biotechnol. 25, 911-920 (2007).